Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | tumor specific glycosylation of MUC1 |
Clinical data | |
Other names | PankoMab-GEX, anti-TA-MUC1 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII |
Gatipotuzumab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.[1] Gatipotuzumab is being developed by Glycotope GMBH [2] and is undergoing a phase II clinical trial for ovarian cancer.[3]
References
- ^ "Gatipotuzumab". Drug Dictionary. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services.
- ^ "Gatipotuzumab – Our first-in-class GlycoBody against the novel tumor-specific TA-MUC1 epitope". Glycotope GmbH.
- ^ Clinical trial number NCT01899599 for "PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer " at ClinicalTrials.gov
External links
- "Gatipotuzumab". Drug Information Portal. U.S. National Library of Medicine.